

<sup>1</sup>Neurology, University of Milan (Milano); <sup>2</sup>Neurology, University College London (London-UK)

**Objectives:** To report the clinical, psychological and neuroradiological features of a family with a mutation in the VCP gene and study any premanifest cognitive or behavioural changes.

**Materials:** Five members of a large family with IBMPFD were recruited at the Dementia Research Centre (University College London Institute of Neurology).

**Methods:** The subjects underwent a standardized interview, neurological examination, neuropsychometry, brain MRI (except for subject 5) and genetic analysis. The baseline MRI scans from the four mutation carrier were compared to a control group of 26 age-matched cognitively normal subjects in a Voxel-based morphometry analysis.

**Results:** Genetic analysis showed a heterozygous c.464G>A nucleotide substitution in exon 5 of the valosin containing protein gene (R155H) in all of the subjects studied. All of them had a progressive myopathy that affected the shoulder and pelvic girdles predominantly. Paget's disease was only found in two subjects (4 and 5). All subjects were cognitively and behaviourally asymptomatic when first seen. Only subject 1 developed behavioural changes typical of frontotemporal dementia (loss of empathy, preference for sweet food and delusions). At the initial assessment only subject 2 showed any abnormalities in neuropsychological testing with evidence of executive dysfunction. Subject 1 developed executive dysfunction on follow-up assessment. Visual assessment of brain MRI was normal for all the members of the family scanned without any atrophy of the frontal or temporal lobes. However, the voxel-based morphometry analysis showed evidence of grey matter atrophy in frontal (premotor, prefrontal and orbitofrontal) and temporal (particularly medial) lobes.

**Discussion:** Inclusion body myopathy (IBM) with Paget's disease of the bone (PDB) and Frontotemporal dementia (FTD) (IBMPFD; OMIM 167320) is a rare autosomal dominant disease caused by mutations in the valosin containing protein (VCP) gene on chromosome 9p13.3-12. According to the literature IBM is present in 90% of carriers, Paget's disease of the bone 50% and FTD only 30%. Our data reflect this distribution but we also showed the presence of presymptomatic executive dysfunction in one subject and evidence for premanifest brain atrophy.

**Conclusion:** Executive dysfunction and brain atrophy can occur presymptomatically in VCP mutation carriers.

**References:**

- G D J Watts, J Wymer, M J Kovach, S G Mehta, S Mumm, D Darvish, A Pestronk, M P Whyte, V E Kimonis. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nature Genetics* (2004) Apr;36(4):377-81
- Miller TD, Jackson AP, Barresi R, Smart CM, Eugenicos M, Summers D, Clegg S, Straub V, Stone J. Inclusion body myopathy with Paget disease and frontotemporal dementia (IBMPFD): clinical features including sphincter disturbance in a large pedigree. *J Neurol Neurosurg Psychiatry* (2009) May;80(5):583-4
- Wehl CC. Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis. *Curr Alzheimer Res.* (2011) May;8(3):252-60

## ORAL HEALTH STATUS AND PERIODONTITIS IN ALZHEIMER'S DISEASE: A POPULATION-BASED, CASE-CONTROL STUDY FROM THE ZABUT AGING PROJECT

A. Aronica<sup>1</sup>, N. Termine<sup>2</sup>, M. Conticelli<sup>1</sup>, G. Campisi<sup>2</sup>, R. Monastero<sup>1</sup>

<sup>1</sup>Department BioNeC, Palermo University (Palermo); <sup>2</sup>Department DICHRON, Palermo University (Palermo)

**Aims:** The aetiopathogenesis for Alzheimer's disease (AD) have not been defined, although inflammation within the brain is thought to play a role. Recent data suggest that peripheral infections contribute to the in-

flammatory state of central nervous system diseases, including cognitive impairment and dementia (1). Periodontitis (PD) is a prevalent, chronic infection involving the tissues supporting the teeth associated with negative, anaerobic bacteria capable of promoting local and systemic release of inflammatory mediators. Aim of the present study was to assess the oral health status and the prevalence/severity of PD in incident subjects evaluated during a population-based, 10-year follow-up study.

**Materials and Methods:** 10-year follow-up data from the Zabuto Aging Project, a population-based study on dementia and cognitive impairment conducted in a rural sicilian population were used for the present case-control study. From the >1030 subjects evaluated at baseline, 130 were subjects with incident dementia according to ICD-10 criteria, and 38 were diagnosed with probable AD according to NINCDS-ADRDA criteria. Seventeen (44%) of the latter were toothless and were excluded from this study. Accordingly, the sample included 21 cases (M: 9; F: 12, age-range 64-93 years) and 21 age- and sex- matched controls (M: 9; F:12; age-range 64-93 years). To evaluate oral health status the Decayed Missed Filled (DMFT) scoring and measurement of the periodontal probing (using Community Periodontal Index - CPI and the Periodontal Screening and Recording Index -PSR) were recorded. The association between AD and oral health indexes was assessed using the  $\chi^2$  test or Fisher's as appropriate. A p value  $\leq 0.05$  was considered statistically significant.

**Results:** DMFT average score was similar in AD ( $18.7 \pm 8.8$ ) and controls ( $19.2 \pm 7.8$ ) ( $p=0.743$ ). Contrarily, differences between cases and controls groups regarding periodontal status approached statistical significance; indeed, high PSR and CPI scores ( $>3$ , indicating moderate-severe PD) were recorded in nearly 78% ( $n=16$ ) of cases and 20% ( $n=10$ ) of controls ( $p=0.06$ ).

**Discussion and Conclusions:** In this rural Sicilian adult-to elderly community an overall poor oral health was frequent with a high DMFT score. The current data moderately support the hypothesis of a higher prevalence and severity of PD among AD patients. To confirm these preliminary results we are currently recruiting a wider sample, including proteomic salivary profiles and RT-PCR-based microbiological investigation on sub-gingival plaque samples, in order to better clarify the role of PD and periodontal pathogens in the AD natural history.

**Reference:**

1. Noble JM, Borrell LN, Papapanou PN et al. Periodontitis is associated with cognitive impairment among older adults: cross-sectional analysis of NHANES-III. *J Neurol Neurosurg Psychiatry* (2011) Nov;80(11):1206-11

## CEFTRIAXONE FOR ALEXANDER'S DISEASE: A 4-YEAR FOLLOW-UP

P. E. Doneddu, E. Sechi, A. Addis, G. Sechi

Department of Clinical and Experimental Medicine, University of Sassari (Sassari)

**Introduction:** Alexander disease (AD) is a rare, usually fatal neurodegenerative disorder, involving primarily astroglial cells in the brain, caused by dominant mutations in the gene encoding glial fibrillary acidic protein. Here we studied the tolerability and therapeutic effects of the chronic use of cycles of ceftriaxone, a beta-lactam antibiotic, on the neuroprotective effects, in a patient affected by adult AD with a rapidly progressive clinical course. In 2010, we reported the successful clinical outcome related to a 20-month course of intravenous, cyclical ceftriaxone, in a patient with adult-onset AD.

**Objectives:** To evaluate the tolerability and therapeutic effects of cycles of ceftriaxone in this patient at a 4-year follow-up.

**Methods:** Gait ataxia, dysarthria, palatal myoclonus, and eye nystagmus/oscillopsia were evaluated every 6 months over a 4-year period. For the first 2 years, without therapy, and for the following 4 years after intravenous ceftriaxone 2 g daily, for 3 weeks monthly during the initial 4 months, then for 15 days monthly. Gait ataxia and dys-